Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hilel Swerdlin

Otolaryngology Kenosha, WI Medical Doctor

NPI 1265529853 CMS profile 883582

6127 Green Bay Rd, Suite 100, Kenosha, WI 53142

Open in the dashboard

General payments

$7,728

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hilel Swerdlin of Kenosha, WI is reported in the CMS Open Payments database as having received $7,728 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,251 60
2024 General $916 44
2023 General $1,228 50
2022 General $1,650 70
2021 General $1,275 46
2020 General $387 18
2019 General $1,020 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hilel Swerdlin
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Hilel Swerdlin were reported at $1,251. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Hilel Swerdlin Otolaryngology median Middle half National median
2019 $1,020 $194 $82–$512 $163
2020 $387 $118 $42–$280 $114
2021 $1,275 $167 $63–$444 $132
2022 $1,650 $216 $84–$545 $149
2023 $1,228 $235 $93–$588 $160
2024 $916 $280 $111–$699 $164
2025 $1,251 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,042 61 payments
  2. GlaxoSmithKline, LLC. $1,218 67 payments
  3. Genzyme Corporation $1,121 48 payments
  4. OptiNose US, Inc. $727 44 payments
  5. Intersect ENT, Inc. $578 14 payments
  6. Medtronic, Inc. $536 17 payments
  7. ALK-Abello, Inc $357 16 payments
  8. Regeneron Healthcare Solutions, Inc. $300 17 payments
  9. Acclarent, Inc $136 3 payments
  10. Lilly USA, LLC $124 8 payments
  11. Other $587 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,653 317 payments
  2. Education $75 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,529 57 payments
  2. NUCALA $1,218 67 payments
  3. XPRESS ENT DILATION SYSTEM $824 23 payments
  4. Xhance $727 44 payments
  5. ENTELLUS - XPRESS ENT DILATION SYSTEM $554 14 payments
  6. SCOPIS ENT $395 15 payments
  7. PROPEL $280 7 payments
  8. TIMOTHY, STANDARDIZED $270 12 payments
  9. DUPIXENT Inflammation And Immunology $242 14 payments
  10. ALTERNARIA TENUIS $218 10 payments
  11. Other $2,738 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

253

Median for Otolaryngology: 297

Drug cost

$3,636

Median for Otolaryngology: $6,314

Branded share of claims

4.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 69 $1,608
Fluticasone Propionate Generic 78 $1,143
Ipratropium Bromide Generic 22 $400
Doxycycline Hyclate Generic 27 $264
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $113
Azithromycin Generic 25 $84
Prednisone Generic 21 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$150,642

Medicare's payments for the services billed

Medicare patients

82

Average age 71

Services billed

1,627

41 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 46%
Diabetes 24%
Depression 23%
Ischemic heart disease 22%
Cancer 22%
Chronic kidney disease 21%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record